Welcome to our dedicated page for Biomark Diagnostics news (Ticker: BMKDF), a resource for investors and traders seeking the latest updates and insights on Biomark Diagnostics stock.
BioMark Diagnostics Inc. (BMKDF) regularly issues news and updates about its work in liquid biopsy-based early cancer detection, with a strong emphasis on lung cancer. The company’s announcements describe progress in applying metabolomics and machine learning to blood-based diagnostics, as well as developments in clinical validation, laboratory capacity, and international collaborations.
Readers of this news feed can follow BioMark’s participation in large-scale clinical studies, such as its role as a core diagnostic partner in the HANSE lung cancer screening trial in Germany and its involvement in multi‑thousand‑patient lung cancer studies in Canada. News items also cover recognition from organizations like ADRIQ and CQDM for multimodal lung cancer screening projects that integrate metabolomic blood tests, clinical data, and artificial intelligence.
Company releases provide detail on peer-reviewed publications, including work accepted in journals such as Frontiers in Oncology that report on machine learning-driven predictive models using pathway-based plasma metabolomic biomarkers. Updates also highlight the expansion of BioMark’s specialty laboratory services in Quebec, equipment upgrades that increase testing capacity, and steps toward laboratory certification and accreditation.
Investors and healthcare professionals can use this page to review announcements on intellectual property milestones, such as patents granted in China and Japan for BioMark’s metabolic liquid biopsy platform, as well as strategic agreements in regions like North Africa. By visiting this news section, users gain a consolidated view of BioMark’s clinical, operational, and strategic developments in oncology diagnostics.
BioMark Diagnostics Inc. (CSE: BUX, FSE: 20B, OTC Pink: BMKDF) has been granted U.S. Patent No. 17/895.69 by the USPTO, strengthening its liquid biopsy technology for cancer management. The patent protects BioMark's SAT1 legacy assay platform for assessing tumor velocity and treatment response in glioblastoma (GBM) and triple-negative breast cancer (TNBC) patients with specific genetic mutations.
Key points:
- GBM market size estimated at $2.80 billion in 2024, expected to reach $4.60 billion by 2029 (CAGR 8%)
- TNBC accounts for 15% of all breast cancers
- BioMark plans to launch a preclinical study for TNBC patients with BRCA mutations
- The patent enhances BioMark's position in developing cancer management solutions
BioMark Diagnostics Inc. (CSE: BUX) (OTC Pink: BMKDF) announced that collaborators from the University of Manitoba will present new research findings on glioblastoma at the 2024 GPEN Conference in Copenhagen. The presentations focus on:
1. Evaluation of hydrogel formulations for delivering siRNA to glioblastoma tumor cells
2. Examination of potential drug biomarker candidates for glioblastoma
The research highlights BioMark's liquid biopsy technology for evaluating minimal residual disease and treatment outcomes in glioblastoma. CEO Rashid Ahmed Bux emphasized their comprehensive approach, including biomarker discovery, novel drug delivery mechanisms, and potential gene knockdown treatments for glioblastoma.
FAQ
What is the current stock price of Biomark Diagnostics (BMKDF)?
What is the market cap of Biomark Diagnostics (BMKDF)?
